Zoetis Takes the Lead in Veterinary AI Diagnostics with Major Vetscan Imagyst Enhancements

Zoetis announces major upgrades to its Vetscan Imagyst platform, enhancing AI diagnostics for blood smears, fecal, and urine sediment tests. These updates improve veterinary care by enabling faster, more accurate results and allowing for individualized patient treatment. With advanced features like white blood cell differential and identification of urinary crystals, Zoetis continues to lead the field of veterinary AI diagnostics.

Key advancements include a significant upgrade to the AI Blood Smear application. The enhanced algorithm now offers the ability to identify and differentiate segmented and band neutrophils, marking the first white blood cell (WBC) differential of its kind in veterinary hematology. Additionally, it will now report aggregate platelets and detect five specific red blood cell (RBC) shape changes, including poikilocytes. These new features open doors to more accurate and actionable diagnostics, improving patient outcomes.

Zoetis has also expanded its AI Fecal analysis capabilities, with the platform now able to recognize and identify Spirometra spp. tapeworms, a crucial development in diagnosing parasitic infections. Furthermore, the AI Urine Sediment update will enable the identification of spermatozoa and quantify three new urinary crystals (ammonium biurate, cystine, and bilirubin), which are indicative of potential urinary pathology.

According to Abhay Nayak, President of Global Diagnostics at Zoetis, “Our customers expect Zoetis to push the limits of what’s possible medically. Expanding testing targets to include parasites such as Spirometra spp., or helping clinicians identify challenging blood cells such as poikilocytes, represent exciting examples of how Zoetis is channeling its innovation investments. The Imagyst platform is dynamic, and we are proud of our ability to leverage customer feedback into next-generation improvements.”

The Vetscan Imagyst platform is widely recognized for its rapid, AI-powered analysis, delivering expert-level results in minutes. Studies have shown that the platform delivers results up to 196 times faster than traditional methods, saving valuable time and resources. One satisfied customer, Dr. Lance Kidder, owner of Sierra Veterinary Hospital, remarked, “The Vetscan Imagyst has been instrumental in making sure we are not only achieving quality results, but quick ones.”

In addition to the fast and efficient results, the platform also provides visually clear and shareable images that reflect the way cells appear microscopically. This feature has been particularly well-received by pet owners, with 100% of focus groups reporting that a visual report of results was important to them.

The power of Vetscan Imagyst goes beyond speed and accuracy—research also highlights its positive impact on revenue. Clinics using the platform have reported up to a 108% increase in revenue, with two additional visits per patient and more treatment options administered. These financial benefits, coupled with faster diagnosis, demonstrate the platform's broad potential for improving both medical outcomes and business performance.

Dr. Richard Goldstein, Global Chief Medical Officer at Zoetis, added, “The small footprint, high-resolution Vetscan Imagyst standardizes diagnostic processes, enabling medical teams to implement simple, efficient workflows with trusted expert-level results. It allows veterinarians to spend more time with their patients and provide the best medicine, improving the experience for both medical teams and pet owners.”

Currently, the Vetscan Imagyst is the only commercially available veterinary diagnostic tool of its kind, offering six unique testing applications. Zoetis is committed to continuously enhancing these capabilities, demonstrating unmatched leadership in the veterinary diagnostics field.

To learn more about Zoetis' diagnostic solutions, visit Zoetis Diagnostics.